medicationSpecial Scenario

GLP-1s and Birth Control

Tirzepatide carries a specific FDA label warning that oral contraceptives may be less effective for 4 weeks after starting and after each dose escalation. Here's exactly what the label says and how to plan around it.

The short answer

Tirzepatide — sold as Zepbound for weight management and Mounjaro for type 2 diabetes — carries a specific label warning that oral hormonal contraceptives may be less effective for 4 weeks after starting the drug and 4 weeks after each dose escalation. The mechanism is delayed gastric emptying. The FDA-labeled mitigation is to either switch to a non-oral contraceptive method (IUD, implant, injection, patch, ring) or add a barrier method (condoms) during those 4-week windows. Semaglutide (Wegovy, Ozempic, Rybelsus) does not carry the same warning because pharmacokinetic studies did not show a clinically significant effect on oral contraceptive exposure.

What to know

The tirzepatide pharmacokinetic study is what drove the label. Eli Lilly conducted a dedicated drug-drug interaction study using a single oral contraceptive containing norgestimate and ethinyl estradiol. After tirzepatide dosing, the maximum concentration (Cmax) of both hormones dropped by 55-66%, and total exposure (AUC) dropped meaningfully too. This is a real, clinically significant pharmacokinetic interaction — not a theoretical concern. It is most pronounced at initiation and at each dose increase because that is when gastric emptying is most slowed.

The 4-week window is built around the time it takes for gastric emptying to re-equilibrate. After a new dose level is reached, gastric emptying gradually accelerates back toward baseline over several weeks. Once steady state is established at a given dose, the effect on oral contraceptive absorption appears to diminish. The label conservatively defines a 4-week window of reduced reliability starting with the first dose of a new strength.

Non-oral methods are not affected by gastric emptying. An intrauterine device (copper or hormonal), a subdermal implant (Nexplanon), a depot injection (DepoProvera), a transdermal patch, or a vaginal ring all bypass the stomach entirely. The label-preferred path is to switch to one of these for someone who is going to be escalating tirzepatide repeatedly — not just temporarily add a backup at every dose change.

Semaglutide is different. Wegovy and Ozempic underwent similar pharmacokinetic studies with oral contraceptives and did not show a clinically meaningful reduction in hormone exposure. The semaglutide label does not carry the same warning. This is not because semaglutide slows gastric emptying less in general — it does — but the specific effect on oral contraceptive absorption in those studies did not reach a threshold for label action. Most clinicians do not advise routine backup for someone on semaglutide and an oral pill.

The pregnancy implications matter. Both semaglutide and tirzepatide are not recommended in pregnancy, with a labeled 2-month washout before trying to conceive. An accidental pregnancy on a GLP-1 — including one caused by reduced oral contraceptive efficacy — is a clinical situation worth avoiding. This is the practical reason the birth-control warning matters more than its short window suggests.

Practical steps

Choosing a method

shield

Switch to non-oral if you're on tirzepatide

An IUD, implant, injection, patch, or ring is not affected by gastric emptying changes. For someone titrating up tirzepatide over months, this is the cleanest answer.

event

If staying on the pill, add a barrier

The label recommendation is a backup barrier method (condoms) for 4 weeks after starting tirzepatide and 4 weeks after each dose escalation. Mark dose-change dates on a calendar.

info

Semaglutide users don't need backup

The Wegovy and Ozempic labels do not include this warning. Standard oral contraceptive reliability applies. The 2-month pre-conception washout still applies if you plan to become pregnant.

Common questions

Common Concerns

Does Wegovy reduce birth control pill effectiveness?expand_more

No. The Wegovy (semaglutide) and Ozempic labels do not include an oral contraceptive warning. Pharmacokinetic studies did not show a clinically significant reduction in hormone exposure. Standard pill reliability applies.

What exactly does the Zepbound label say?expand_more

The Zepbound prescribing information warns that oral hormonal contraceptive exposure can decrease with tirzepatide and that patients on oral contraceptives should switch to a non-oral contraceptive method, or add a barrier method of contraception, for 4 weeks after starting tirzepatide and for 4 weeks after each dose escalation.

Why does tirzepatide affect the pill but not semaglutide?expand_more

Both drugs slow gastric emptying, but the specific pharmacokinetic studies showed a larger reduction in oral contraceptive exposure with tirzepatide than with semaglutide. The exact reason isn't fully established — it may relate to magnitude or timing of gastric emptying effects, or to the specific hormones tested.

Does an IUD or implant need a backup window?expand_more

No. The label specifically addresses oral hormonal contraceptives. IUDs, subdermal implants, depot injections, transdermal patches, and vaginal rings bypass the stomach and are not affected by delayed gastric emptying. They do not require a backup window on tirzepatide.

Does this apply to emergency contraception?expand_more

Plan B (levonorgestrel) and Ella (ulipristal) are oral. While the label warning was studied with combined oral contraceptives, the conservative reading is that emergency contraception efficacy could also be reduced on tirzepatide during the 4-week windows. A copper IUD is the most reliable emergency contraceptive option in any context and would not be affected.

Keep exploring

Browse all GLP-1 guides.